Floatz logo

Epirubicin

Recurrent Acute Lymphoblastic Leukemia

OHSU Knight Cancer InstitutePhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Recurrent Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
Sorafenib
Nanfang Hospital, Southern Medical University
Phase 3BB
Pembrolizumab
OHSU Knight Cancer Institute
Phase 2BB
Humax-Cd20
M.D. Anderson Cancer Center
Phase 2B
su011248
OHSU Knight Cancer Institute
Phase 2B
Palbociclib
Tanja Andrea Gruber
Phase 1/2B

View all 48 →

Same molecule, other indications

Epirubicin is also rated in:

Recurrent Breast CarcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Lung Non-Small Cell Squamous CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Advanced/Metastatic Gastroesophageal AdenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →